The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Hepatic steatosis steadily increased in patients with HIV and HCV coinfection despite curative treatment with DAA therapy.

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

MASH patients with clinically significant liver fibrosis (stages F2 and F3) are at high risk for progression to cirrhosis, which places them at greater risk for hepatocellular carcinoma ...

Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...